ArticleJournal of translational medicine2025
Construction of lactylation (LA) risk signature in prostate cancer based on 4D fast DIA L-lactated quantitative genomics.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLactylation (LA) plays a crucial role in regulating protein stability, angiogenesis, and immune modulation. Global lactylation of proteins in prostate cancer cells is a key event in tumor progression. This study aimed to explore the characteristics of LA in patients with prostate cancer (PRAD) and construct a LA-related risk model to predict prognosis.
methodsLA-related genes in prostate cancer were screened through quantitative lactylation proteomics of human tissues from Beijing Tongren Hospital, Capital Medical University. Based on the TCGA and GEO databases, patients were divided into two LA-related gene clusters. Principal component analysis (PCA) was used to identify the heterogeneity of the grouping, and differentially expressed genes (DEGs) between the clusters were identified. A LA risk model was constructed using Lasso-Cox regression analysis, and its efficacy was verified in the TCGA, GSE116918, and GSE70769 cohorts through K-M curves, receiver operating characteristic (ROC) curves, and nomograms. The most representative gene, KCNMA1, was selected for in vitro and animal experiments to verify its association with prostate cancer.
resultsBased on quantitative lactylation proteomics, two LA clusters were identified in prostate cancer and were significantly associated with prognosis. A total of 122 DEGs were screened to construct a gene risk model. The K-M curves verified the differences between the high - and low - risk groups of the model in the test group and the training cohort (test group: P = 0.025; training group: P < 0.001). The ROC curve verified that the prognostic model had good accuracy. The nomogram integrating staging and LA risk factors showed high accuracy and reliability in predicting the prognosis of prostate cancer. The expression of KCNMA1 in PCa was significantly lower than that in NATs, and its expression level decreased with the increase in grading. In cell experiments, overexpression of KCNMA1 promoted the infiltration of M1 macrophages by inhibiting the RAS/RAF/MEK/ERK signaling pathway, thereby inhibiting the proliferation, migration, and invasion of prostate cancer cells. Animal experiments demonstrated that overexpression of KCNMA1 inhibited the growth rate of tumors.
conclusionThe LA risk model constructed in this study can effectively predict the prognosis of prostate cancer and is expected to become a new type of test scoring criterion. KCNMA1 is expected to become a novel target for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.